AVITA MEDICAL INC (AVH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AVH

AVH - AVITA MEDICAL INC

Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.12
Index:

Avita Medical is developing and marketing a range of regenerative skin products. It is headquartered in California and listed on the ASX and NASDAQ.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$5.10

19 Nov
2026

0.380

OPEN

$5.00

8.05%

HIGH

$5.10

701,224

LOW

$4.97

TARGET
$5.65 10.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . BIO . BOT . COV . CSL . CUV . DXB . GSS . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
AVH: 1
Title FY26
Forecast
FY27
Forecast
EPS (cps) - 63.4 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

$ 

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-54.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx111.1 M
Book Value Per Share xxxxxxxxxxxxxxx-16.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-48.4 M
Net Profit Margin xxxxxxxxxxxxxxx-67.85 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-258.41 %
Return on Assets xxxxxxxxxxxxxxx-70.65 %
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-103.54 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-49.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx66 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx69 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx27 M
Price To Book Value xxxxxxxxxxxxxxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.7 M
Capex % of Sales xxxxxxxxxxxxxxx1.54 %
Cost of Goods Sold xxxxxxxxxxxxxxx20 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx156 M
Research & Development xxxxxxxxxxxxxxx32 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

09/11/2026

3

Upgrade to Hold from Sell

$5.00

-1.96%

Morgans raises its target for Avita Medical to $5.00 from $2.20 and upgrades to Hold from Sell following stronger-than-expected third-quarter results. Management also raised FY26 revenue guidance to US$92m–US$94m.

The broker highlights 53% revenue growth, flat operating expenses and sharply reduced cash outflows for the quarter, with cash flow breakeven now approaching.

Improved liquidity removes immediate funding concerns, the analyst suggests.

Morgans sees significant long-term upside, provided execution remains strong, supported by Avita's clinically proven Recell technology, improved US reimbursement certainty and expanded payment support.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -23.62 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -8.59 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

09/11/2026

1

Buy

$5.92

16.08%

Canaccord Genuity maintains a Buy rating for Avita Medical with its target price increased to $5.92 from $4.74 following a record third-quarter sales result.

The analyst notes total revenue reached US$26.1m, a 53% year-on-year increase that beat the broker's estimate by 15%, driven by strong organic utilisation and expanded account penetration for the RECELL product line.

Canaccord highlights that the Centers for Medicare & Medicaid Services confirmed a Final Rule establishing national physician reimbursement for RECELL, replacing the previous regional approach and positioning the franchise to effectively convert its growing addressable market.

Following upgraded full-year revenue guidance of US$92m to US$94m, Canaccord raises its FY26 sales estimate toward the top end of this range while noting the company reiterated its goal to achieve operating cash-flow breakeven in the fourth quarter.

The target price upgrade reflects an expansion in the applied valuation multiple from 5.0x to 6.0x FY27 EV/sales, as Canaccord assesses that recent reimbursement developments and growing attachment rates can support sustained revenue growth above 20%.

AVH STOCK CHART